주메뉴 바로가기 컨텐츠 바로가기 하단 바로가기


 

학술논문지

  • 국내학술논문지
  • 국외학술논문지
 
작성일 : 14-09-21 15:09
연구단계 1단계 :1년차
논문제목(영문) A longitudinal study of SLC6A4 DNA promoter methylation and poststroke depression
국내외구분 국외 SCI여부 SCI
연구책임자역활 주저자 논문기여율 30%
주저자명 Kim JM
교신저자명 Yoon JS
공동저자명 Stewart R, Kang HJ, Kim SW, Shin IS, Kim HR, Shin MG, Kim JT, Park MS, Cho KH
게제년월일 2013-09-01
ISSN 0022-3956
Impact Factor 4.092
학술지명 J Psychiatr Res
서지사항 0집 / 47권 / 9호,   페이지(1222 - 1227)
병기표기 단독
Acknowledgement
기재여부

※ Acknowledgement가 기재된 논문만 연구과제의 성과로 인정.
- 국문 표기 : "본 연구는 보건복지부 보건의료연구개발사업의 지원에 의하여 이루어진 것임. (HI13C1527)"
- 영문 표기 : "This study was supported by a grant of the Korean Health Technology R&D Project,
(HI13C1527) Ministry of Health & Welfare, Republic of Korea. "
요약초록문
(Abstract) 입력
Serotonin transporter gene (SLC6A4) has been shown to play an important role in the pathophysiology of mood disorders including poststroke depression (PSD). SLC6A4 expression is influenced by DNA methylation status and the SLC6A4 linked promoter region (5-HTTLPR) polymorphism. This study aimed to investigate whether SLC6A4 methylation status was associated with depression ascertained at two weeks and one year after stroke taking into account the 5-HTTLPR polymorphism. A total of 286 patients were evaluated two weeks after stroke, and 222 (78%) were followed one year later. Depression was diagnosed according to DSM-IV criteria, and depression severity was assessed by the Hamilton Depression Rating Scale (HAMD) at each evaluation point. The effects of SLC6A4 methylation status on PSD status and HAMD scores were investigated using multivariate logistic regression models and partial correlation tests, respectively. Analyses were repeated after stratification by 5-HTTLPR genotype groups ('l/l or l/s' and 's/s'). Higher SLC6A4 promoter methylation status was independently associated with PSD both at 2 weeks and more prominently at 1 year after stroke, and was significantly associated with the worsening of depressive symptoms over one year. These findings were significant only in the presence of the 5-HTTLPR s/s genotype. SLC6A4 methylation profile was supported as a potential diagnostic and prognostic biomarker for PSD; associations with SLC6A4 methylation status may represent a target for drug development.